Statute Details
- Title: Communicable Diseases Agency Act 2025
- Act Code: CDAA2025
- Act Type: Act of Parliament
- Number: No. 4 of 2025
- Long Title: An Act to establish the Communicable Diseases Agency and to make consequential amendments to certain other Acts.
- Assent Date: 3 February 2025
- Commencement: 1 April 2025 (with power for Minister to appoint by Gazette notification)
- Status (as provided): Current version as at 26 Mar 2026
- Parts: Part 1 (Preliminary); Part 2 (Establishment, functions and powers); Part 3 (Constitution and membership); Part 4 (Decision-making); Part 5 (Personnel matters); Part 6 (Financial provisions); Part 7 (General); Part 8 (Transfer of undertakings and personnel); Part 9 (Consequential amendments)
- Key Provisions (by heading): Establishment and governance of the Agency; decision-making procedures; personnel and secrecy; financial powers; offences and enforcement mechanics; transfer of undertakings/personnel; consequential amendments
What Is This Legislation About?
The Communicable Diseases Agency Act 2025 (“CDAA 2025”) is a Singapore statute that creates a dedicated statutory body—the Communicable Diseases Agency (“the Agency”)—and sets out how it is governed, funded, staffed, and empowered to carry out its public health role. In plain terms, the Act provides the legal “machinery” for a specialised agency to coordinate and execute functions relating to communicable (infectious) diseases, including surveillance and disease control activities.
While the extract provided focuses on the Agency’s institutional framework (establishment, governance, decision-making, personnel, finance, and transfer arrangements), the Act’s design indicates a broader policy objective: to strengthen Singapore’s communicable disease preparedness and response by consolidating relevant capabilities within a single statutory entity. The Act also anticipates that the Agency will interact with other public bodies and will be subject to ministerial oversight through directions.
Importantly for practitioners, the Act is not merely organisational. It includes provisions on secrecy, protection from personal liability, and offences (including corporate and association liability). It also contains a transfer mechanism to move undertakings, employees, secondees, and records to the Agency—typical of legislation that restructures public functions. Finally, it includes consequential amendments and transitional savings, which are critical when existing legal regimes are modified to accommodate the new Agency.
What Are the Key Provisions?
1. Establishment and legal status of the Agency (Sections 3–4). The Act establishes the Communicable Diseases Agency (section 3) and provides that the Agency is a body corporate (section 4). This matters legally because a body corporate can generally hold property, enter contracts, sue and be sued, and act through its authorised officers and committees. For lawyers advising government-linked entities, the body corporate status is a foundational determinant of capacity and liability.
2. Objective, functions, and powers (Sections 5–6). The Act sets out the Agency’s objective and functions (section 5) and confers powers (section 6). Although the extract does not reproduce the detailed content of these provisions, the headings and definitions show that the Agency’s remit is tied to communicable disease prevention, management, and control. The Act also defines key concepts such as “infectious disease” and “surveillance,” signalling that the Agency’s statutory role includes collecting, analysing, and interpreting data for disease prevention and control.
3. Ministerial directions and oversight (Section 7). Section 7 provides for directions of the Minister. This is a common feature in Singapore’s statutory boards and agencies: the Minister can direct the Agency on matters within its functions and powers. Practically, this means that compliance advice should not only focus on the Agency’s internal governance but also on ministerial direction instruments, which may shape operational priorities and legal risk.
4. Governance: membership, appointment, disqualification, and removal (Sections 10–18). Part 3 sets out the constitution and membership of the Agency. It covers membership of the Agency (section 10), appointment of members (section 11), disqualification (section 12), appointment of the Chairperson and Deputy Chairperson (section 13), and how to handle premature vacancies (section 14). It also provides for acting appointments (section 15), removal of members (section 16), and resignation (section 17). Section 18 addresses the validity of acts—a crucial “continuity” provision that protects the Agency’s decisions from being invalidated due to defects in membership or appointment processes.
5. Decision-making: meetings, quorum, voting, and execution of documents (Sections 23–28). Part 4 establishes how the Agency makes decisions. It provides for procedure generally (section 23), notice of meetings (section 24), quorum (section 25), presiding at meetings (section 26), voting (section 27), and execution of documents (section 28). For practitioners, these provisions are important when assessing whether a particular decision or contract was properly authorised. If a dispute arises about whether the Agency acted within its internal rules, the meeting and voting provisions become central.
6. Committees and delegation (Sections 29–32). The Agency may appoint committees (section 29) and committees must follow specified proceedings (section 30). Section 31 enables delegation of functions or powers to a delegate. Section 32 then addresses the validity of a delegate’s acts. This is particularly relevant for legal review of operational decisions: if the Agency delegates authority, lawyers should verify (i) that delegation was properly made, and (ii) that the delegate’s actions fall within the delegated scope.
7. Personnel matters: Chief Executive, officers, secrecy, and liability protection (Sections 33–36). The Act provides for appointment of the Chief Executive (section 33) and officers (section 34). It includes a preservation of secrecy (section 35), which is a key compliance requirement in public health contexts where sensitive personal and health data may be handled. Section 36 provides protection from personal liability, which typically shields individuals acting in good faith within their official capacity from personal exposure. For counsel, these provisions affect both risk allocation and the drafting of internal policies and confidentiality undertakings.
8. Financial provisions: accounts, investment, and borrowing (Sections 37–43). Part 6 covers financial year (section 37), revenue and property (section 38), bank accounts (section 39), financial accounts and records (section 40), power of investment (section 41), issue of shares (section 42), and borrowing power (section 43). Even without the detailed text, the structure indicates that the Agency’s financial autonomy is regulated through statutory controls. Practitioners advising on procurement, funding, or contractual arrangements should consider how borrowing and investment powers may affect the Agency’s financial commitments and governance approvals.
9. General offences and enforcement mechanics (Sections 44–48). Part 7 includes composition of offences (section 44), offences by corporations (section 45), offences by unincorporated associations or partnerships (section 46), service of documents (section 47), and regulations (section 48). These provisions are significant for compliance and enforcement. Corporate liability rules (section 45) are particularly relevant when advising regulated entities that may be required to comply with communicable disease-related obligations under the broader legal framework.
10. Transfer of undertakings and personnel (Sections 49–53). Part 8 provides for the transfer of undertakings to the Agency (section 50), transfer of employees and secondees (section 51), general preservation of employment terms (section 52), and transfer of records (section 53). This is a critical transitional framework for employment law and data governance. The preservation of employment terms reduces the risk of adverse changes to staff conditions due solely to the restructuring. The transfer of records also raises practical issues for confidentiality, data retention, and continuity of regulatory obligations.
11. Consequential amendments and transitional savings (Sections 54–55). Section 54 provides for consequential amendments to other Acts, and section 55 includes saving and transitional provisions. These clauses are essential to avoid legal gaps or unintended consequences during the transition to the new statutory regime.
How Is This Legislation Structured?
The Act is organised into nine Parts, moving from foundational definitions to operational governance and then to transition and amendments:
Part 1 (Preliminary) contains the short title and commencement (section 1) and interpretation (section 2). The interpretation section is particularly important because it defines terms such as “Agency,” “infectious disease,” “surveillance,” “public body,” and “officer,” which will govern how the Act is read in practice.
Part 2 establishes the Agency and sets out its objective, functions, and powers, including ministerial directions and branding/name provisions.
Part 3 sets out the Agency’s constitution: membership, appointment, disqualification, Chairperson roles, acting arrangements, removal, resignation, and validity of acts.
Part 4 governs decision-making: meetings, quorum, voting, execution of documents, committees, and delegation.
Part 5 addresses personnel: Chief Executive appointment, officers, secrecy, and personal liability protection.
Part 6 provides financial rules: accounts, investment, and borrowing.
Part 7 contains general legal provisions including offences, service of documents, and regulation-making powers.
Part 8 provides for transfer of undertakings, employees, secondees, and records, with preservation of employment terms.
Part 9 makes consequential amendments to other Acts and includes transitional savings.
Who Does This Legislation Apply To?
The Act primarily applies to the Communicable Diseases Agency itself—its members, committees, officers, delegates, and the Chief Executive. It governs how the Agency is constituted and how it exercises its functions and powers. It also applies to persons who interact with the Agency in the course of its statutory activities, particularly where secrecy obligations, offences, or service of documents provisions are engaged.
In addition, the transfer provisions in Part 8 affect employees and secondees whose undertakings and services are transferred to the Agency. The Act’s employment preservation clause indicates that the legislation is designed to manage the human resource transition without destabilising existing employment terms. Entities that may become subject to offences or corporate liability provisions (Part 7) should also take note, as the Act’s enforcement framework can influence compliance strategies.
Why Is This Legislation Important?
For practitioners, the CDAA 2025 is important because it creates a central statutory institution for communicable disease governance and response. The legal significance lies not only in the Agency’s existence but in the detailed procedural safeguards and governance architecture that determine how decisions are authorised and how accountability is structured.
From a compliance and litigation perspective, the Act’s provisions on meetings, quorum, voting, execution of documents, delegation, and validity of acts are particularly relevant. They can determine whether an Agency decision is challengeable on procedural grounds. Similarly, secrecy provisions and personal liability protections affect how confidential information is handled and how individuals may be exposed (or insulated) from claims arising from official actions.
From an advisory standpoint, the transfer of undertakings, employees, secondees, and records is a major operational and legal pivot. Lawyers should expect that existing contracts, employment arrangements, and data governance practices may need to be reviewed to ensure continuity and compliance with the new statutory framework. Finally, consequential amendments and transitional savings reduce the risk of legal uncertainty during implementation, but they also require careful reading to understand how other statutes are modified.
Related Legislation
- Communicable Diseases Agency Act 2025 (the Act itself; including its full text and schedule)
- Town Councils Act 1988 (referenced in the definition of “public body” for exclusion of Town Councils)
Source Documents
This article provides an overview of the Communicable Diseases Agency Act 2025 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.